SPRED1 Antibody (M23-P2G3): sc-101392

SPRED1 Antibody (M23-P2G3) is a mouse monoclonal IgG1 kappa light chain antibody that detects SPRED1 in mouse, rat, and human samples through applications such as western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), and enzyme-linked immunosorbent assay (ELISA). Anti-SPRED1 antibody (M23-P2G3) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. SPRED1, or sprouty-related, EVH1 domain containing 1, is a 444 amino acid protein characterized by the presence of one KBD domain, one sprouty domain, and one WH1 domain. SPRED1 is primarily localized to the cell membrane and cholesterol-rich membrane raft fractions, where SPRED1 plays a crucial role as a negative regulator of the ERK (extracellular signal-regulated kinase) signaling pathway, which is vital for cell proliferation and differentiation. By inhibiting the growth-factor-mediated activation of ERK, SPRED1 helps maintain cellular homeostasis and prevent uncontrolled cell growth, which is particularly important in the context of cancer and other proliferative disorders. SPRED1 can function as a homodimer or form heterodimers with SPRED2, further enhancing regulatory capabilities. Mutations in the SPRED1 gene are associated with neurofibromatosis type 1-like syndrome (NFLS), an autosomal dominant condition characterized by multiple café-au-lait spots, axillary freckling, and macrocephaly, underscoring SPRED1′s significance in developmental processes and disease pathology.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

SPRED1 Antibody (M23-P2G3) References:

1. Spred is a Sprouty-related suppressor of Ras signalling.  |  Wakioka, T., et al. 2001. Nature. 412: 647-51. PMID: 11493923
2. Spred-1 negatively regulates interleukin-3-mediated ERK/mitogen-activated protein (MAP) kinase activation in hematopoietic cells.  |  Nonami, A., et al. 2004. J Biol Chem. 279: 52543-51. PMID: 15465815
3. Expression and subcellular localization of Spred proteins in mouse and human tissues.  |  Engelhardt, CM., et al. 2004. Histochem Cell Biol. 122: 527-38. PMID: 15580519
4. Distinct requirements for the Sprouty domain for functional activity of Spred proteins.  |  King, JA., et al. 2005. Biochem J. 388: 445-54. PMID: 15683364
5. The Sprouty-related protein, Spred-1, localizes in a lipid raft/caveola and inhibits ERK activation in collaboration with caveolin-1.  |  Nonami, A., et al. 2005. Genes Cells. 10: 887-95. PMID: 16115197
6. Spreds, inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors.  |  Yoshida, T., et al. 2006. Oncogene. 25: 6056-66. PMID: 16652141
7. Germline loss-of-function mutations in SPRED1 cause a neurofibromatosis 1-like phenotype.  |  Brems, H., et al. 2007. Nat Genet. 39: 1120-6. PMID: 17704776
8. Tesk1 interacts with Spry2 to abrogate its inhibition of ERK phosphorylation downstream of receptor tyrosine kinase signaling.  |  Chandramouli, S., et al. 2008. J Biol Chem. 283: 1679-1691. PMID: 17974561
9. Spred1 and TESK1--two new interaction partners of the kinase MARKK/TAO1 that link the microtubule and actin cytoskeleton.  |  Johne, C., et al. 2008. Mol Biol Cell. 19: 1391-403. PMID: 18216281
10. Review and update of SPRED1 mutations causing Legius syndrome.  |  Brems, H., et al. 2012. Hum Mutat. 33: 1538-46. PMID: 22753041
11. SPRED1 Is Downregulated and a Prognostic Biomarker in Adult Acute Myeloid Leukemia.  |  Zhang, R., et al. 2020. Front Oncol. 10: 204. PMID: 32175275
12. Spred1 deficit promotes treatment resistance and transformation of chronic phase CML.  |  Qiao, J., et al. 2022. Leukemia. 36: 492-506. PMID: 34564700

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-SPRED1 Antibody (M23-P2G3) has 2 citations in a variety of scientific publications.

Primary antibodies like Anti-SPRED1 Antibody (M23-P2G3) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

SPRED1 Antibody (M23-P2G3) Specifications

Alternate Product Name: SPRED1

Product Clone Name: M23-P2G3

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG₁ kappa light chain

Amino Acids: 420-428

Epitope Target: SPRED1

Epitope Species: human

Product Reactivity/Detection: SPRED1

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, ELISA

Vialing Information: Each vial contains 200 µg IgG₁ kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 2 citations in various scientific publications

Available Conjugates/Forms for SPRED1 Antibody (M23-P2G3): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin